Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast Evenity Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    Evenity (romosozumab-aqqg) Coverage Criteria

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and Part B coverage of Evenity for osteoporosis in postmenopausal women at high risk for fracture or patients who have failed or cannot tolerate other osteoporosis therapies. It applies to providers requesting coverage under the Total Care Advantage Medicare Part B benefit.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyEvenity (romosozumab-aqqg) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization with medical records documenting prior therapies and responses, diagnosis confirmation, and an endocrinologist prescriber.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsMaximum covered duration per lifetime
    1 mgBilling unit for HCPCS J3111
    EndocrinologistRequired prescriber specialty
    NoneAge restriction

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Covered Uses and Coverage Limits

    Covered Uses

    Evenity is covered for the treatment of osteoporosis when one of the following covered-use pathways applies:

    ONE of the following

    • Postmenopausal osteoporosis at high fracture risk

      • Patient is a postmenopausal woman with osteoporosis.
      • High fracture risk is demonstrated by ONE of the following

        • History of osteoporotic fracture.
        • Multiple risk factors for fracture.
    • Patient has failed or is intolerant to other available osteoporosis therapy.

    Cumulative use of Evenity exceeding 12 months is not covered.

    Billing and Coding

    HCPCS Description Billing Units/How SuppliedHCPCSCovered
    J3111Evenity (romosozumab-aqqg) Billing unit: 1 mg.

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Evenity requests. The medication must be prescribed by an endocrinologist, and the request must include the required supporting documentation.

    • Prescriber restriction: endocrinologist.
    • Submit the prior authorization request with supporting medical records.
    Documentation Required

    Required Medical Records

    Submit medical records documenting prior osteoporosis therapies and the patient’s responses to treatment, along with clinical evidence confirming the osteoporosis diagnosis.

    • Document prior therapies and responses to treatment.
    • Include supporting clinical evidence confirming the diagnosis.

    Drug and Policy Background

    Evenity (romosozumab-aqqg) is a humanized IgG2 monoclonal antibody and sclerostin inhibitor indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, or in patients who have failed or are intolerant to other available osteoporosis therapy.

    Clinical Definitions

    High Risk for Fracture
    DefinitionHigh risk for fracture
    Qualifying historyHistory of osteoporotic fracture
    Alternative qualificationMultiple risk factors for fracture

    Initial Authorization Criteria

    Initial Authorization Criteria

    Initial coverage is available when all of the following requirements are met:

    Initial Evenity authorization

    • Covered osteoporosis indication

      • Postmenopausal woman at high risk for fracture: The patient is a postmenopausal woman with osteoporosis and is at high risk for fracture.

        High risk for fracture is defined as a history of osteoporotic fracture or multiple risk factors for fracture.

      • Failure or intolerance of other therapy: The patient has osteoporosis and has failed or is intolerant to other available osteoporosis therapy.
    • Required medical records:

    Prerequisite Osteoporosis Therapy

    StepRequirementFailure or intolerance criteria
    1The patient must have failed or be intolerant to other available osteoporosis therapy when seeking coverage through that indication pathway.Failure of other available osteoporosis therapy or intolerance to other available osteoporosis therapy.

    Lifetime Quantity Limit

    Quantity Limits
    DrugEvenity (romosozumab-aqqg)
    Maximum covered duration12 months per lifetime
    ExclusionCumulative use of Evenity of more than 12 months is not covered
    Policy Summary
    PayerGold Coast Health Plan
    PolicyEvenity (romosozumab-aqqg) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization with medical records documenting prior therapies and responses, diagnosis confirmation, and an endocrinologist prescriber.
    SourceLink
    On This Page
    Covered Uses and Coverage LimitsBilling and CodingAuthorization and Documentation RequirementsDrug and Policy BackgroundClinical DefinitionsInitial Authorization CriteriaPrerequisite Osteoporosis TherapyLifetime Quantity Limit
    Denial Risk

    12-Month Lifetime Limit

    Cumulative use of Evenity beyond 12 months per lifetime is not covered.

    • Coverage duration: 12 months per lifetime.
    • Requests exceeding the lifetime limit are not covered.
    Medical records document prior therapies and responses to treatment and confirm the diagnosis.
  1. Prescriber requirement: Evenity is prescribed by an endocrinologist.